Currently set to Index
Currently set to Follow

Comparative Therapy

Human vs Canine AD

Duration 2h30
Live online ISAD symposium on Tuesday, October 19, 2021


➜ Please register (free) to watch the recording.

Faculty

  • Thierry OLIVRY, DV, PhD, Dip European & American College VD
  • Pascal PRÉLAUD, DV, Dip European College VD
  • Chie TAMAMOTO MOCHIZUKI, DVM, PhD, Dip Asian College CVD
  • Claude FAVROT, DV, MS, Diplomate European College of VD, Zürich
  • Lisa BECK, MD PhD
  • Kenji KABASHIMA, MD PhD
  • Martin STEINHOFF, MD PhD
  • Peter SCHMID-GRENDELMEIER, ISAD
  • Andreas WOLLENBERG, ISAD
  • Amy PALLER, ISAD
  • Roberto TAKAOKA, ISAD
  • Alain TAÏEB, ISAD

Programme of the meeting

02:00 pm Introduction
Alain TAÏEB
PRESENTATIONS (1 h 30)
10 mn CAD and HAD: same disease with different therapeutic approach
Pascal PRELAUD
15 mn How dupilumab has changed the treatment paradigm for severe HAD
Lisa BECK
15 mn Lokivetmab (anti-IL31): proactive and reactive use
Thierry OLIVRY and Chie TAMAMOTO MOCHIZUKI
15 mn Anti IL31Rα therapy in HAD and prurigo nodularis
Kenji KABASHIMA
10 mn Oclacitinib: fast, not furious
Pascal PRELAUD
10 mn Glucocorticoids, ciclosporine, oclacitinib and anti-IL31: new paradigms of systemic treatment of AD
Thierry OLIVRY
15 mn Pruritus biology and the new generation of JAK inhibitors vs anti TH2 cytokine biologics
Martin STEINHOFF
GENERAL DISCUSSION (1 h)
Moderators: AW AP PSG TO PP JR RT CF
Conclusions
Thierry OLIVRY & Alain TAÏEB